Vybion

Vybion is a biotechnology firm focused on developing innovative therapies using Intrabodies to target neurodegenerative diseases, such as Huntington's disease, aiming to modify disease progression through advanced intrabody technology. Founded in 1993 in Ithaca, US, Vybion specializes in creating therapeutic Intrabodies. The company has made one notable deal in 1998, when it received financing from Cayuga Venture Fund. Lee Henderson is both the Founder and CEO, bringing a wealth of experience to the firm.

Vybion specializes in the development of Intrabodies specifically designed to target neurodegenerative diseases. The company's primary product, INT41, is an intrabody delivered via adeno-associated virus (AAV) that treats Huntington's disease by blocking gene dysregulation and inhibiting toxic mutant Huntingtin protein fragments. Vybion's Intrabodies are scFv fragments addressing critical intracellular events in neurodegenerative pathologies, primarily targeting research institutions and pharmaceutical companies in North America and Europe engaged in therapeutic development. Vybion's revenue model is based on partnerships with pharmaceutical companies and research institutions for developing therapies for neurodegenerative diseases.

These partnerships typically take the form of collaborations or licensing agreements, facilitating the integration of Vybion's proprietary intrabody technology into broader therapeutic pipelines. Although specific pricing details are not disclosed, the revenue structure includes milestone payments and royalties from future sales of their therapeutic candidates. Vybion plans to leverage recent funding from the August 1998 deal with Cayuga Venture Fund to support its ongoing research and development initiatives. The company aims to expand its product offerings with new Intrabody therapies targeting additional neurodegenerative conditions and to enter new markets in Europe and North America by 2025.